clinical trial · NCT01338415
FUTURE 3 Study Extension
Actelion·phase3·completed·n = 58
Pulmonary Arterial HypertensionBosentan
brief summary
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).
started
Mar 8, 2011
primary completion
Aug 13, 2014
completion
May 29, 2020
last updated
Mar 30, 2025
official title
A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol